Literature DB >> 29297710

Expression of N-cadherin and β-catenin in human meningioma in correlation with peritumoral edema.

Robert Rutkowski1, Robert Chrzanowski1, Magdalena Trwoga2, Jan Kochanowicz1, Grzegorz Turek1, Zenon Mariak1, Joanna Reszeć3.   

Abstract

OBJECTIVE: To analyze the expression of β-catenin and N-cadherin in large series of meningioma cases and to investigate their correlation with peritumoral brain edema (PTBE).
MATERIALS AND METHODS: Study group consists of 154 patients diagnosed with intracranial meningioma divided into: low-grade (G1) and high-grade (G2 or G3) group. PTBE was graded into four groups (0, I, II, III) using Steinhoff classification. The expression of N-cadherin, β-catenin was analyzed and graded based on the positive ratio of immunoreactivity. The results were analyzed statistically.
RESULTS: 104 cases were low-grade and 50 high-grade meningiomas. PTBE was observed in 103(66.8 %) cases: 57 grade I, 44 grade II and 2 grade III. Positive N-cadherin expression was found only in the membrane of the neoplastic cells in 50(48.1%) cases of low-grade, and in 34(68%) of high-grade group. In low-grade meningioma, β-catenin expression was observed within the cytoplasm and nucleus in 54(51.9%) cases. In high-grade meningiomas, β-catenin expression was observed in 33(66%) tumors only within the nucleus. N-cadherin expression was observed in 36 cases with PTBE grade I, 28 with grade II and 2 with grade III. β-catenin expression was observed in 40 cases with PTBE grade I, 24 with grade II and 2 with grade III. The results were statistically significant.
CONCLUSIONS: Significant N-cadherin expression especially in high-grade meningioma group was found. β-catenin expression was the most evident in the nucleus rather than in cytoplasm. The degree of PTBE correlated with the N-cadherin and β-catenin expression and was the most prominent in high-grade meningioma group.

Entities:  

Keywords:  N-cadherin; meningioma; peritumoral brain edema; β-catenin

Mesh:

Substances:

Year:  2018        PMID: 29297710     DOI: 10.1080/00207454.2018.1424153

Source DB:  PubMed          Journal:  Int J Neurosci        ISSN: 0020-7454            Impact factor:   2.292


  6 in total

1.  Identification of HMGCR as the anticancer target of physapubenolide against melanoma cells by in silico target prediction.

Authors:  Hai-Yan Wang; Pian Yu; Xi-Sha Chen; Hui Wei; Shi-Jie Cao; Meng Zhang; Yi Zhang; Yong-Guang Tao; Dong-Sheng Cao; Feng Qiu; Yan Cheng
Journal:  Acta Pharmacol Sin       Date:  2021-09-29       Impact factor: 7.169

2.  Peritumoral edema correlates with mutational burden in meningiomas.

Authors:  Corey M Gill; Joshua Loewenstern; John W Rutland; Hanane Arib; Margaret Pain; Melissa Umphlett; Yayoi Kinoshita; Russell B McBride; Joshua Bederson; Michael Donovan; Robert Sebra; Mary Fowkes; Raj K Shrivastava
Journal:  Neuroradiology       Date:  2020-08-12       Impact factor: 2.804

3.  Peripheral Blood Occludin Level as a Biomarker for Perioperative Cerebral Edema in Patients with Brain Tumors.

Authors:  Shuhai Shi; Jingli Cheng; Chunyang Zhang; Tao Liang; Yunxin Zhang; Yongxing Sun; Ying Zhao; Weili Li; Baoguo Wang
Journal:  Dis Markers       Date:  2020-08-19       Impact factor: 3.434

4.  Efficacy of Bevacizumab in High-Grade Meningiomas: A Retrospective Clinical Study.

Authors:  Xuexue Bai; Xiaomin Liu; Jun Wen
Journal:  Neuropsychiatr Dis Treat       Date:  2022-08-06       Impact factor: 2.989

5.  EPS364, a Novel Deep-Sea Bacterial Exopolysaccharide, Inhibits Liver Cancer Cell Growth and Adhesion.

Authors:  Yun Wang; Ge Liu; Rui Liu; Maosheng Wei; Jinxiang Zhang; Chaomin Sun
Journal:  Mar Drugs       Date:  2021-03-22       Impact factor: 5.118

6.  Evaluation of AQP4/TRPV4 Channel Co-expression, Microvessel Density, and its Association with Peritumoral Brain Edema in Intracranial Meningiomas.

Authors:  Konstantinos Faropoulos; Afroditi Polia; Chrisi Tsakona; Eleanna Pitaraki; Athanasia Moutafidi; George Gatzounis; Martha Assimakopoulou
Journal:  J Mol Neurosci       Date:  2021-02-04       Impact factor: 3.444

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.